Inclusion Criteria:  Agree to follow the trial treatment plan and visit plan, join the group voluntarily, and sign a written informed consent form; Age ≥18 and ≤75 years old at the time of signing the informed consent form, regardless of gender; Eastern Cooperative Oncology Group performance status scoring criteria (ECOG) PS of 0 ~ 1 points (see Appendix 1 for criteria);  Exclusion Criteria:  Have received chemotherapy, radiotherapy, biological therapy, endocrine therapy, immunotherapy and other anti-tumor treatments within 4 weeks before using the study drug for the first time, except for the following items: Have received other unmarketed clinical research drugs or treatments within 4 weeks before using the research drug for the first time; Patients who have previously received treatment with PD-1/PD-L1 and TGF-β bifunctional antibody drugs or received treatment with PD-1/PD-L1 combined with TGF-β target drugs; Patients who have undergone major organ surgery (excluding needle biopsy) or have significant trauma within 4 weeks before using the study drug for the first time,or required elective surgery during the trial period; Use of immunomodulatory drugs within 14 days before the first use of study drugs, including but not limited to thymosin, interleukin-2, interferon, etc.;